MediciNova, Inc. (MNOV): Price and Financial Metrics

MediciNova, Inc. (MNOV): $1.68

0.06 (-3.45%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add MNOV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#185 of 402

in industry

MNOV Price/Volume Stats

Current price $1.68 52-week high $2.71
Prev. close $1.74 52-week low $1.68
Day low $1.68 Volume 47,800
Day high $1.73 Avg. volume 42,981
50-day MA $1.91 Dividend yield N/A
200-day MA $2.17 Market Cap 82.40M

MNOV Stock Price Chart Interactive Chart >


MediciNova, Inc. (MNOV) Company Bio


MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. The company was founded in 2000 and is based in La Jolla, California.


MNOV Latest News Stream


Event/Time News Detail
Loading, please wait...

MNOV Latest Social Stream


Loading social stream, please wait...

View Full MNOV Social Stream

Latest MNOV News From Around the Web

Below are the latest news stories about MEDICINOVA INC that investors may wish to consider to help them evaluate MNOV as an investment opportunity.

MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update New Data for MN-166 in GBM Presented at SNO On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) were presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) ( Lauko et al., 2023 ). The Phase

Yahoo | November 27, 2023

The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...

Yahoo | November 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning!

William White on InvestorPlace | November 20, 2023

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner Co

Yahoo | November 19, 2023

MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on a

Yahoo | October 27, 2023

Read More 'MNOV' Stories Here

MNOV Price Returns

1-mo -9.19%
3-mo -25.33%
6-mo -21.86%
1-year -30.29%
3-year -72.41%
5-year -81.31%
YTD -18.05%
2022 -23.51%
2021 -49.05%
2020 -21.96%
2019 -17.50%
2018 26.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!